Quantcast
Channel: MassDevice
Browsing all 1713 articles
Browse latest View live

Image may be NSFW.
Clik here to view.

EOFlow wins breakthrough status for wearable closed-loop insulin delivery tech

Korean medtech company EOFlow said last week that it won breakthrough status from the FDA for its closed-loop automated insulin delivery system for people with Type 1 diabetes. The EOPancreas system...

View Article


Image may be NSFW.
Clik here to view.

Surmodics shares down following FDA’s paclitaxel device update

Surmodics (NSDQ:SRDX) shares fell last week after the FDA wrote a letter to doctors detailing a trend of heightened mortality in people with peripheral artery disease who were treated with...

View Article


Image may be NSFW.
Clik here to view.

Sage wins historic FDA nod for postpartum depression therapy

Sage Therapeutics (NSDQ:SAGE) this week won FDA approval for the first medicine indicated to treat postpartum depression. The Cambridge, Mass.-based company’s injection therapy, Zulresso, is slated to...

View Article

Image may be NSFW.
Clik here to view.

Novo Nordisk seeks FDA nod for oral diabetes pill

Novo Nordisk (NYSE:NVO) said this week that it submitted applications to the FDA for its oral formulation of semaglutide, a once-daily glucagon-like peptide-1 receptor agonist therapy. The company is...

View Article

Image may be NSFW.
Clik here to view.

Novocure launches pivotal ovarian cancer trial

Novocure (NSDQ:NVCR) said today that it kicked off a Phase 3 pivotal trial testing its Tumor Treating Fields therapy combined with paclitaxel in people with recurrent, platinum-resistant ovarian...

View Article


Image may be NSFW.
Clik here to view.

Novartis launches COPD inhalers in China

Novartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease. The Ultibro Breezhaler system is a once-daily...

View Article

Image may be NSFW.
Clik here to view.

Dyve Bioscience touts proof-of-concept study for transdermal painkiller

Dyve Bioscience this week touted data from a human proof-of-concept pilot study of its transdermal sodium bicarbonate therapy for pain reduction in people with acute gout flare. The study enrolled 24...

View Article

Image may be NSFW.
Clik here to view.

Study examines usability of hybrid closed-loop insulin pump

Data from an 83-person study of Medtronic‘s (NYSE:MDT) MiniMed 670G hybrid closed-loop insulin pump showed that nearly one-fifth of participants stopped using the device after struggling with the...

View Article


Image may be NSFW.
Clik here to view.

Medtronic responds to usability concerns for its MiniMed 670G insulin pump

Medtronic (NYSE:MDT) responded to a study presented this week which highlighted usability concerns with its MiniMed 670G automated insulin pump, writing that the company had “made many enhancements to...

View Article


Image may be NSFW.
Clik here to view.

Breath Therapeutics launches Ph3 trial for inhaled liposomal cyclosporine A...

Privately-held Breath Therapeutics said today that it kicked off a Phase III clinical program for its liposomal formulation of cyclosporine A for the treatment of bronchiolitis obliterans syndrome. The...

View Article

Image may be NSFW.
Clik here to view.

Teva wins EU nod for Ajovy migraine prophylactic

Teva (NYSE:TEVA) said yesterday that it won EC Marketing Authorization for its Ajovy pre-filled syringe injection meant to serve as a prophylaxis for migraines in adults who experience at least four...

View Article

Image may be NSFW.
Clik here to view.

Cigna lowers insulin price to $25 per month

Under pressure from patients and the FDA, Cigna (NYSE:CI) and Express Scripts said today that they will lower the price of insulin to $25 per month for some patients. Three firms — Eli Lilly, Novo...

View Article

FDA nixes Evoke Pharma’s gastro nasal spray

The FDA has rejected Evoke Pharma’s (NSDQ:EVOK) application for a metoclopramide nasal spray for diabetic women with gastroparesis. The Solana Beach, Calif. company’s stock price tumbled 40% on the...

View Article

Browsing all 1713 articles
Browse latest View live